CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Rapastinel (formerly GLYX-13)drug
Likely dose
Rapastinel (formerly GLYX-13) 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02267629
NCT02267629Phase 2Completed
CompareCT.gov

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

New York State Psychiatric Institute·interventional·Posted Oct 17, 2014·Updated Jul 18, 2017

In Brief

A Phase 2 clinical trial evaluating Rapastinel (formerly GLYX-13) for Obsessive-Compulsive Disorder (OCD). Completed, enrolled 7 participants across 1 site.

Detailed Summary

This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder (OCD)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 17, 2014
Enrollment StartOct 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.7 years ago

Interventions

Rapastinel (formerly GLYX-13)drug

10 mg/kg IV Rapastinel (formerly GLYX-13)